Updated Overall Survival and Exploratory Analysis From Randomized, Phase II EVAN Study of Erlotinib Versus Vinorelbine Plus Cisplatin Adjuvant Therapy in Stage IIIA Epidermal Growth Factor Receptor+ Non–Small-Cell Lung Cancer

Yue, Dongsheng; Xu, Shidong; Wang, Qun; Li, Xiaofei; Shen, Yi; Zhao, Heng; Chen, Chun; Mao, Weimin; Liu, Wei; Liu, Junfeng; Ma, Haitao; Li, Qiang; Yang, Yue; Liu, Yongyu; Chen, Haiquan; Zhang, Zhenfa; Zhang, Bin; Wang, Changli

doi:10.1200/jco.22.00428

Cited by 28 publications

(17 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…EGFRm NSCLC. Meanwhile, the EVAN study was published, demonstrating for the first time a clinically meaningful overall survival (OS) improvement with adjuvant erlotinib compared with chemotherapy in Stage III EGFRm NSCLC, with median OS and 5-year OS rates of 84.2 months and 84.8%, respectively [39]. The aboveupdated results further confirm the role of adjuvant targeted therapy.…”

Section: Gene Alterationmentioning

confidence: 81%

Annual progress of clinical research on targeted therapy for nonsmall cell lung cancer in 2022

Huang

Zhang

2023

Cancer Innovation

View full text Add to dashboard Cite

With the rapid development of lung cancer molecular detection and precision therapy, targeted therapy has covered the entire process of diagnosis and treatment of nonsmall cell lung cancer patients. Overall mortality from lung cancer has decreased significantly over the past 20 years, especially since the introduction of targeted drugs in 2013. In 2022, targeted therapy for lung cancer has developed rapidly. The optimization of treatment modes and the exploration of new target drugs such as antibody‐drug conjugates will broaden the selection range of nonsmall cell lung cancer patients with positive driver genes. This article reviews the latest advances in targeted therapy for driver gene‐positive lung cancer in 2022.

show abstract

Section: Gene Alterationmentioning

confidence: 81%

Annual progress of clinical research on targeted therapy for nonsmall cell lung cancer in 2022

Huang

Zhang

2023

Cancer Innovation

View full text Add to dashboard Cite

show abstract

“…DNAH9 , which encodes the outer-dynein-arm heavy chain, was found to be involved in cell–cell adhesion, which markedly impacts cancer cell invasion and migration. DNAH9 was found to be associated with prognosis in patients with epidermal-growth-factor-receptor-positive non-small-cell lung cancer 55 , 56 , uterine corpus endometrial carcinoma 57 , or chronic myeloid leukemia 58 , and with the pathogenesis of myelodysplastic syndrome/acute myeloid leukemia 59 , 60 , hepatocellular carcinoma 61 , esophageal squamous-cell carcinoma 62 , and pure invasive micropapillary carcinoma of the breast 63 .…”

Section: Discussionmentioning

confidence: 99%

Gene signature developed for predicting early relapse and survival in early-stage pancreatic cancer

et al. 2023

View full text Add to dashboard Cite

Background The aim of this study was to construct a predictive signature integrating tumour-mutation- and copy-number-variation-associated features using machine learning to precisely predict early relapse and survival in patients with resected stage I–II pancreatic ductal adenocarcinoma. Methods Patients with microscopically confirmed stage I–II pancreatic ductal adenocarcinoma undergoing R0 resection at the Chinese PLA General Hospital between March 2015 and December 2016 were enrolled. Whole exosome sequencing was performed, and genes with different mutation or copy number variation statuses between patients with and without relapse within 1 year were identified using bioinformatics analysis. A support vector machine was used to evaluate the importance of the differential gene features and to develop a signature. Signature validation was performed in an independent cohort. The associations of the support vector machine signature and single gene features with disease-free survival and overall survival were assessed. Biological functions of integrated genes were further analysed. Results Overall, 30 and 40 patients were included in the training and validation cohorts, respectively. Some 11 genes with differential patterns were first identified; using a support vector machine, four features (mutations of DNAH9, TP53, and TUBGCP6, and copy number variation of TMEM132E) were further selected and integrated to construct a predictive signature (the support vector machine classifier). In the training cohort, the 1-year disease-free survival rates were 88 per cent (95 per cent c.i. 73 to 100) and 7 per cent (95 per cent c.i. 1 to 47) in the low-support vector machine subgroup and the high-support vector machine subgroup respectively (P < 0.001). Multivariable analyses showed that high support vector machine was significantly and independently associated with both worse overall survival (HR 29.20 (95 per cent c.i. 4.48 to 190.21); P < 0.001) and disease-free survival (HR 72.04 (95 per cent c.i. 6.74 to 769.96); P < 0.001). The area under the curve of the support vector machine signature for 1-year disease-free survival (0.900) was significantly larger than the area under the curve values of the mutations of DNAH9 (0.733; P = 0.039), TP53 (0.767; P = 0.024), and TUBGCP6 (0.733; P = 0.023), the copy number variation of TMEM132E (0.700; P = 0.014), TNM stage (0.567; P = 0.002), and differentiation grade (0.633; P = 0.005), suggesting higher predictive accuracy for prognosis. The value of the signature was further validated in the validation cohort. The four genes included in the support vector machine signature (DNAH9, TUBGCP6, and TMEM132E were novel in pancreatic ductal adenocarcinoma) were significantly associated with the tumour immune microenvironment, G protein-coupled receptor binding and signalling, cell–cell adhesion, etc. Conclusion The newly constructed support vector machine signature precisely and powerfully predicted relapse and survival in patients with stage I–II pancreatic ductal adenocarcinoma after R0 resection.

show abstract

“…OS data have not yet been published [ 9 ]. Additional phase 2 trials [ 7 , 44 ] and phase 3 trials [ 8 ] evaluated the effect of TKI therapy in the adjuvant treatment of completely resected NSCLC with EGFR mutations. Despite significantly improved DFS, prolonged OS could not be demonstrated.…”

Section: Discussionmentioning

confidence: 99%

Landscape of Genomic Alterations and PD-L1 Expression in Early-Stage Non-Small-Cell Lung Cancer (NSCLC)—A Single Center, Retrospective Observational Study

Stephan-Falkenau

Streubel

Mairinger

et al. 2022

IJMS

View full text Add to dashboard Cite

Precision oncology and immunotherapy have revolutionized the treatment of advanced non-small-cell lung cancer (NSCLC). Emerging studies show that targeted therapies are also beneficial for patients with driver alterations such as epidermal growth factor receptor (EGFR) mutations in early-stage NSCLC (stages I–IIIA). Furthermore, patients with elevated programmed death-ligand 1 (PD-L1) expression appear to respond favorably to adjuvant immunotherapy. To determine the frequency of genomic alterations and PD-L1 status in early-stage NSCLC, we retrospectively analyzed data from 2066 unselected, single-center patients with NSCLC diagnosed using next-generation sequencing and immunohistochemistry. Nine-hundred and sixty-two patients (46.9%) presented with early-stage NSCLC. Of these, 37.0% had genomic alterations for which targeted therapies have already been approved for advanced NSCLC. The frequencies of driver mutations in the early stages were equivalent to those in advanced stages, i.e., the rates of EGFR mutations in adenocarcinomas were 12.7% (72/567) and 12.0% (78/650) in early and advanced NSCLC, respectively (p = 0778). In addition, 46.3% of early-stage NSCLC cases were PD-L1-positive, with a tumor proportion score (TPS) of ≥1%. With comparable frequencies of driver mutations in early and advanced NSCLC and PD-L1 overexpression in nearly half of patients with early-stage NSCLC, a broad spectrum of biomarkers for adjuvant and neoadjuvant therapies is available, and several are currently being investigated in clinical trials.

show abstract

Updated Overall Survival and Exploratory Analysis From Randomized, Phase II EVAN Study of Erlotinib Versus Vinorelbine Plus Cisplatin Adjuvant Therapy in Stage IIIA Epidermal Growth Factor Receptor+ Non–Small-Cell Lung Cancer

Cited by 28 publications

References 21 publications

Annual progress of clinical research on targeted therapy for nonsmall cell lung cancer in 2022

Annual progress of clinical research on targeted therapy for nonsmall cell lung cancer in 2022

Gene signature developed for predicting early relapse and survival in early-stage pancreatic cancer

Landscape of Genomic Alterations and PD-L1 Expression in Early-Stage Non-Small-Cell Lung Cancer (NSCLC)—A Single Center, Retrospective Observational Study

Contact Info

Product

Resources

About